LONDON (ShareCast) - (Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced successful toxicity studies and control of blood Clever-1 positive monocytes - precursor cells to tumour associated macrophages in large preclinical models - on Thursday.
The AIM-traded firm said the toxicity studies were designed to fulfil regulatory requirements for three-week interval intravenous administration of Clevegen, typical for other anti-cancer antibodies currently in use.

It described FP-1305 as a humanised IgG4 monoclonal antibody produced in CHO-cells by Faron collaborator Abzena.

The FP-1305 drug product, in its final formulation, was administered as a single dose at 3, 30 and 100 mg/kg.

Faron said no toxicologically relevant changes were observed in any subject, with no major changes were observed after treatment with FP-1305 in T lymphocytes subsets.

The binding of Clevegen to its receptor on circulating CD14+ monocytes was confirmed by investigating the receptor occupancy, the recovery of which occurred between three and 20 days after dosing in a dose-dependent manner.

No relevant changes were said to have been present in cytokines, with no anti-drug antibodies detected in any subject.

As a result, Faron said the highest dose of 100 mg/kg was considered the no-observed-adverse-effect-level.

"We are very encouraged to find out about the good safety profile of our wholly-owned asset Clevegen and the high NOAEL concentration," said Faron chief executive officer Dr Markku Jalkanen.

"We were also delighted to learn that Clevegen administration blocks Clever-1 on circulating monocytes, which are one group of our target cells in our MATINS Phase I/II clinical trial.

"Our plan is now to file the MATINS clinical trial application (CTA) during Q3 2018 and, as previously announced, initiate this first Clevegen human trial in Q4 2018."

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE